Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Tzardi

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Anticancer Research|August 15, 1998
Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissueK Stefanaki, M Tzardi, C Kouvidou, et al.
Anticancer Research|July 1, 1997
P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expressionC Kouvidou, K Stefanaki, Y Dai, et al.
Anticancer Research|September 1, 1996
Expression of p53 and mdm-2 proteins in Hodgkin's Disease. Absence of correlation with the presence of Epstein-Barr virusM Tzardi, C Kouvidou, I Panayiotides, et al.
The Pharmacogenomics Journal|October 26, 2016
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapyS Pontikakis, C Papadaki, M Tzardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2006
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapyJ Souglakos, A Kalykaki, L Vamvakas, et al.
British Journal of Cancer|July 16, 2009
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancerJ Souglakos, J Philips, R Wang, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Anticancer Research|August 15, 1998
Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissueK Stefanaki, M Tzardi, C Kouvidou, et al.
Anticancer Research|July 1, 1997
P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expressionC Kouvidou, K Stefanaki, Y Dai, et al.
Anticancer Research|September 1, 1996
Expression of p53 and mdm-2 proteins in Hodgkin's Disease. Absence of correlation with the presence of Epstein-Barr virusM Tzardi, C Kouvidou, I Panayiotides, et al.
The Pharmacogenomics Journal|October 26, 2016
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapyS Pontikakis, C Papadaki, M Tzardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2006
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapyJ Souglakos, A Kalykaki, L Vamvakas, et al.
British Journal of Cancer|July 16, 2009
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancerJ Souglakos, J Philips, R Wang, et al.
Pageof 6